Format

Send to

Choose Destination
Annu Rev Med. 2010;61:317-28. doi: 10.1146/annurev.med.080608.100623.

Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.

Author information

1
HCC Translational Research Laboratory, Barcelona-ClĂ­nic Liver Cancer Group, Institut d'Investigacions Biomediques Agusto Pi i Sunyer (IDIBAPS), Liver Unit, Hospital Clinic, Barcelona, Spain. augusto.villanueva@ciberehd.org

Abstract

The genomic era is changing the understanding of cancer, although translation of the vast amount of data available into decision-making algorithms is far from reality. Molecular profiling of hepatocellular carcinoma (HCC), the most common cause of death among cirrhotic patients and a fast-growing malignancy in Western countries, is enabling the advancement of novel approaches to disease diagnosis and management. Most HCCs arise on a cirrhotic liver, and predictably, an accurate genomic characterization will allow the identification of procarcinogenic signals amenable to selective targeting by chemopreventive strategies. Molecular diagnosis is currently feasible for small tumors, but it has not yet been formalized by scientific guidelines. Molecular treatment is a reality: Sorafenib confers unprecedented survival benefits in patients at advanced stages. Genomic information from tumor and nontumoral tissue will aid prognosis prediction and facilitate the identification of oncogene addiction loops, providing the opportunity for more personalized medicine.

PMID:
20059340
PMCID:
PMC3677155
DOI:
10.1146/annurev.med.080608.100623
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center